ERBB2 and breast carcinoma: This finding indicates that biological behaviour rather than systemic treatment defines the risk for early or late development of BM in patients with HER-2-positive breast cancer (Burstein et al, 2005; Pestalozzi et al, 2006; Lin and Winer, 2007).